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Abstract
Background: Canine atopic dermatitis (cAD) is a common chronic and pruritic skin disease in dogs. The development
of cAD involves complex interactions between environmental antigens, genetic predisposition and a number of
disparate cell types. The aim of the present study was to perform comprehensive analyses of peripheral blood of AD
dogs in relation to healthy subjects in order to determine the changes which would be characteristic for cAD.
Results: The number of cells in specific subpopulations of lymphocytes was analyzed by flow cytometry, concentration
of chosen pro- and anti-inflammatory cytokines (IL-4, IL-10, IL-13, TNF-α, TGF-β1) was determined by ELISA; and
microarray analysis was performed on RNA samples isolated from peripheral blood nuclear cells of AD and healthy
dogs. The number of Th cells (CD3+CD4+) in AD and healthy dogs was similar, whereas the percentage of Tc (CD3
+CD8+) and Treg (CD4+CD25+ Foxp3+) cells increased significantly in AD dogs. Increased concentrations of IL-13 and
TNF-α, and decreased levels of IL-10 and TGF-β1 was observed in AD dogs. The level of IL-4 was similar in both groups
of animals. Results of the microarray experiment revealed differentially expressed genes involved in transcriptional
regulation (e.g., transcription factors: SMAD2, RORA) or signal transduction pathways (e.g., VEGF, SHB21, PROC) taking
part in T lymphocytes lineages differentiation and cytokines synthesis.
Conclusions: Results obtained indicate that CD8+ T cells, beside CD4+ T lymphocytes, contribute to the development
of the allergic response. Increased IL-13 concentration in AD dogs suggests that this cytokine may play more important
role than IL-4 in mediating changes induced by allergic inflammation. Furthermore, observed increase in Treg cells in
parallel with high concentrations of TNF-α and low levels of IL-10 and TGF-β1 in the peripheral blood of AD dogs point
at the functional insufficiency of Treg cells in patients with AD.
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Background
Canine atopic dermatitis (cAD) is a chronic and recur-
rent inflammatory and pruritic skin disease which affects
10 % of canine population. This disease is one of the
most prevalent skin diseases in dogs, with characteristic
clinical features most commonly associated with IgE-
mediated hypersensitivity to environmental allergens. Its
pathogenesis is associated with a complex of interactions
between environmental factors, genetic predisposition,
defective skin barrier and immunological hyperreactivity
[1, 2]. AD develops as a result of defective innate and
adaptive immune responses. The inflammatory reaction
is caused by biphasic T cell polarization. The initial acute
T-helper 2 (Th2) response is characterized by predomin-
ant secretion of interleukins: IL-4, IL-5 and IL-13 result-
ing in recruitment of eosinophils into inflammatory site,
and activation of B lymphocytes, which are stimulated to
produce IgE. The allergen-specific IgE binding to mast
cells causes degranulation of these cells. The secreted in-
flammatory mediators lead to inflammation. In human
AD (hAD) acute phase leads to Th1-driven chronic phase.
The activation of Th1 cells causes IFN-γ and IL-2, IL-12
secretion [3]. In dogs only the initial Th2 type response is
typically found, and it is difficult to recognize the typical
Th1 type response, but rather a mixed Th1-Th2 response
is observed [4, 5]. Until recently studies have been focused
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on the imbalance of Th1 and Th2 cells, but now in hu-
man, as well as veterinary medicine multiple lymphocyte
phenotypes are considered to play a role in the immune
response during AD. Th9 and Th17 cells control local tis-
sue inflammation secreting proinflammatory cytokines
and chemokines [6, 7]. In scientific literature information
about the role of CD8+ T cytotoxic (Tc) cells is scarce.
Some studies indicate that CD8+ T cells may contribute to
development of human AD skin lesion, because they infil-
trate to the skin very early, prior other leukocyte subsets
[8]. However, Olivry et al. [9] and Sinke et al. [10] reported
infiltration of CD4+ and CD8+ T cells in both lesional and
non-lesional cAD skin, but CD4+ T cells was predominant
in lesional skin. Regulatory T cells (Tregs) are a hetero-
genic subpopulation of lymphocytes. In humans two main
Treg cells subsets are distinguished: naturally occurring
thymic selected Tregs characterized by the expression of
CD4+CD25+ Foxp3+ and type -1 IL-10 secreting Tregs
(Trl1) induced in the periphery under tolerogenic condi-
tions. Tregs are characterized by the ability to secrete
anti-inflammatory cytokines, such as IL-10 and TGF-β,
resulting in suppression of allergen induced specific T cells
activation, and also suppression of effector cells of allergic
inflammation, such as must cells, basophils, and eosino-
phils, as well as IgE production [7, 11–13]. Although
many studies have been exploiting the functions of the
subpopulations of Treg cells and their activity, the
knowledge is still insufficient and requires further in-
vestigation. While a broad array of molecules have been
implicated in Treg cell mediated suppression in vitro
these pathways remain mostly unexplored in vivo. In
the case of human Treg cells it has been shown that
they are highly heterogenous and difficult to identify
[14]. Moreover, rigorous analyses of the functional
properties of these cells have been hindered by the lack
of reliable surface markers. Natural Treg cells are argu-
ably the best characterized Treg type in humans. In the
case of cAD we know even less.
Cytokines play the major role in development, differ-
entiation and function of cells (lymphocytes, mast cells,
dendritic cells, and eosinophils), which take part in the
immune response. During allergic inflammation, already
secreted and newly synthesized cytokines are released
contributing to the pathology observed in allergic dis-
eases. They exert their effects by binding to specific cell
surface receptors and inducing the expression of
relevant target genes.
Until now research on cAD has been focused on lym-
phocytes and other leukocytes subsets, as well as cyto-
kines and inflammatory mediators in regard to their
contribution to the developing immune response in pa-
tients. Some studies aimed to reveal the molecular
mechanism of cAD on transcriptomic level [15–17], and
the majority of these studies were carried out on the
lesional and non-lesional skin samples, allowing to analyze
site directly affected by inflammation. On the other hand
use of blood samples as the investigated material gives an
overview of organism’s reaction on allergen. Furthermore,
collection of blood samples is easier and less painful for a
dog. Thus, in the present study we aimed to determine a
comprehensive picture of the state of organism affected by
cAD in order to investigate complex interactions between
multiple genes and environmental factors inducing this
disease. For this purpose we analyzed the profile of per-
ipheral blood lymphocytes, plasma levels of cytokines and
the transcription profile of peripheral blood nuclear cells
in AD and clinically healthy dogs.
Methods
Animals
This study complies with national and institutional
guidelines on the use of animals in clinical research ac-
cording to the Polish legal act from January 21st, 2005
(Ustawa o doświadczeniach na zwierzętach z dnia 21
stycznia 2005 r. (Dz. U. z 2005 r. Nr 33, poz. 289 z
późn.zm.)), concerning experiments performed on client
owned animals. All dogs were patients of Small Animal
Clinic at Warsaw University of Life Sciences. Before en-
rolling a dog into the study an informed consent from
its owner was obtained and a high standard of care was
adhered to throughout each examination. In the case of
AD dogs research was carried out as part of routine vet-
erinary diagnostic procedure. Dogs included in control
group were blood donors from “Milusia” Veterinary
Blood Bank who were submitted to the Small Animal
Clinic for routine checkup.
Twenty privately owned dogs of various breeds, with
cAD (13 females and seven males) were included in this
study. The breeds were: Labrador retriever (3), Golden
retriever (2), American Staffordshire terrier (2), Boxer
(2), West Highland white terrier, American Bulldog,
French Bulldog, Bull Terrier, Small Munsterlander,
Dachshund, German shepherd, crossbreeds (3). Their
age ranged between 1 and 8 years (mean age: 3.8 years).
Eight healthy dogs served as a control group (3 females
and 5 males), their age ranging between 3 and 8 years
(mean age: 4.6 years). The following breeds were included
in control group: American Staffordshire terrier (2), Lab-
rador retriever (2), Bulldog, Great Dane, Staffordshire Bull
Terrier, Weimaraner.
cAD diagnosis and sample collection
Diagnosis of cAD was based on compatible history and
clinical signs determined using Willemse and Prélaud
diagnostic criteria, completed by Favrot criteria as
follows: pruritus sine material, indoor lifestyle and the
exclusion of other causes of pruritus ongoing for at least
one year.
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In all dogs with chronic pruritus other causative fac-
tors were excluded, i.e.,: skin parasites (Sarcoptic mange,
Demodectic mange, flea allergic dermatitis). Bacterial
pyoderma and Malassezia dermatitis were excluded on
the basis of negative results of in vitro culture assays.
The role of food antigens as a cause of the skin condi-
tion was assessed using elimination diets for 6–8 weeks.
Clinical diagnosis of atopic dermatitis was confirmed by
serological allergy testing (IDEXX allergic panel test) and
intradermal skin testing (Artuvetrin test set, Netherlands).
No anti-inflammatory drugs were given for at least 3 weeks
prior serological test and intradermal test.
All dogs, which were classified to the investigated group
had positive reactions in serological allergy testing and
intradermal skin testing. Peripheral blood samples were
collected just before the dogs were subjected to intrader-
mal skin test, thus at the stage when clinical signs of AD
were visible. Hematological, morphological and biochem-
ical blood tests were conducted on samples of qualified
patients. Each dog with AD, as well as the animals in-
cluded in control group showed morphological parame-
ters of blood within the reference value range.
The blood which was designated to the cytometric or
transcriptomic analyses and ELISA tests was collected
once, and separated into portions which were then used in
particular analyses. The blood samples were collected from
client-owned dogs during routine veterinary examinations.
Blood sampling and separation of peripheral blood
mononuclear cells (PBMC)
Peripheral blood was collected into EDTA anticoagulant
tubes. PBMC were isolated from whole blood by density
gradient centrifugation in histopaque-1077 using a proto-
col provided with ACCUSPIN System-HISTOPAQUE-
1077 (Sigma-Aldrich, St. Louis, MO, USA).
Analysis of lymphocyte subpopulations by flow
cytometry
The lymphocyte subpopulations were analyzed by flow
cytometry (FACS Aria II, BD Bioscience, San Jose, CA,
USA). Two commercially available sets of antibodies
(Dog T Lymphocyte cocktail and Dog Activated T
Lymphocyte Cocktail, BD Pharmingen™, USA) were used
to determine the number of T, Th, Tc, activated T cells
and B lymphocytes. Dog T Lymphocyte cocktail com-
prised: APC-conjugated anti-CD3; PE-conjugated anti-CD4
and FITC-conjugated anti-CD8 antibodies. Dog Activated
T Lymphocyte cocktail included 3 antibodies, namely:
APC-conjugated anti-CD3; FITC-conjugated clone CTL
2.58 generated by using whole cell immunizations of IL-2
dependent feline T cell lines stimulated with PHA and Con
A and reacting with dog T cell activation marker; and PE-
conjugated LSM 11.425 antibody generated against cells de-
rived from canine peripheral lymph nodes and used as a
prognostic tool in dog B cell lymphoma studies. Freshly iso-
lated PBMC were suspended in 100 μL of phosphate buff-
ered saline (PBS) and 10 μL of appropriate antibodies were
added. PBMC were incubated at room temperature for
30 min in dark, next the cells were washed in PBS and ana-
lyzed using BD FACSAria™ II flow cytometer (BD Biosci-
ences, USA). Data were collected from 20,000 lymphocytes.
The population of lymphocytes was first gated based on
morphological characteristics: forward scatter (FSC) and
side scatter (SSC) (gate P1). Cells located in gate P1 were
then analyzed in regard to their positive staining with
appropriate antibodies. Unstained cells were used as
negative control. The results of T and B cells were
expressed as the percentage of cells within the gating
area of lymphocytes (P1) and the results of Th and Tc
cells are presented as the percentage of CD3+ cells. The
CD4+/CD8+ ratio was calculated based on the number
of lymphocytes expressing CD3+CD4+ markers vs. the
number of cells expressing CD3+CD8+ markers.
Treg cells analysis by flow cytometry
In order to determine the number of Treg lymphocytes
freshly isolated PBMC were first stained for 30 min with
antibodies against two surface markers: APC-conjugated
anti-CD4 monoclonal antibody (mAb, clone: YKIX302.9;
eBioscience, San Diego, CA) and FITC-conjugated anti-
canine CD25 mAb (clone: P4A10; eBioscience, San Diego,
CA). Appropriate isotypic controls (Rat IgG2a: APC,
Mouse IgG1:FITC) were used as negative controls. Then,
cells were permeabilized in fixation/permeabilization buf-
fer for 18 h at 4 °C in the dark. After incubation cells were
stained intracellularly for Foxp3 for 30 min using cross-
reactive, directly conjugated anti-mouse/rat Foxp3 PE
mAb (clone: FJK-16 s; eBioscience, San Diego, CA) or iso-
type control (Rat IgG2a: PE). Fixation and permabilization
of cells was performed using a set of buffers (Foxp3/Tran-
scription FactorStaining Buffer Set, eBioscience, San Diego,
CA) recommended by the producer for (eBioscience)
Foxp3 staining. The stained cells were analyzed using flow
cytometry. The population of lymphocytes was first gated
on the basis of FSC vs SSC. The percentage of CD4+CD25
+Foxp3+ (Treg) cells was quantified within the population
of lymphocytes positively stained with anti-CD4+ antibody.
Measurement of cytokine concentration in plasma by
ELISA
The concentration of cytokines: IL-2, IL-4, IL-10, IL-13,
TNF-α TGF-β 1and IFN-γ in plasma were determinated
by ELISA. For all cytokines except IFN-γ dog specific
tests from USCN Life Science (CLOUD-CLONE CORP.,
Wuhan, China) were used, and IFN-γ concentration was
determined using Canine IFN-gamma Quantikine ELISA
Kit (R&D System, Minnesota, USA). The detection limit
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was 5.6 pg/mL for IL-13, 5.6 pg/mL for IL-4, 5.8 pg/ml
for IL-2, 5.9 pg/ml for IL-10, 6.2 pg/ml for TNF-α and
TGF-β 1, 60 pg/ml for IFN-γ. ELISAs were performed
according to the instructions of the kits producers.
Statistical analyses of the results of flow cytometric
and ELISA analyses were performed using GraphPad
Prism version 5.00 (GraphPad Software, Inc., USA). Stat-
istical significance was calculated by unpaired t-test.
Results with P value ≤0.05 were considered significant.
Microarray analysis
Blood samples were collected from AD and healthy dogs
into Rneasy Protect Animal Blood Tubes (Qiagen, USA).
Total RNA from peripheral blood nuclear cells was iso-
lated using a Rneasy Protect Animal Blood Kit (Qiagen,
USA). Additionally, contamination with DNA was elimi-
nated by DNAse I digestion included as an additional step
of the isolation protocol. The quantity of RNA was mea-
sured by NanoDrop (NanoDrop Technologies, USA). The
analysis of final RNA quality and integrity was performed
using Agilent 2100 Bioanalyzer (USA) and RNA 6000
Nano Kit (Agilent, Germany). To ensure optimal data
quality, only RNA samples with RIN number ≥7.8 were
included in the analysis.
The analysis of gene expression profile was performed
using Canine (V2) Gene Expression Microarray, 4x44K
(Agilent Technologies, USA) and Agilent Technologies
Reagent Set according to the manufacturer’s procedure.
RNA Spike In Kit (Agilent Technologies, USA) was used
as an internal control, the Low Input Quick Amp Label-
ing Kit was applied to amplify and label (Cy3 or Cy5)
target RNA to generate complementary RNA (cRNA)
for oligo-microarrays. Gene Expression Hybridization
Kit was used to fragmentation and hybridization and
Gene Expression Wash Buffer Kit was used for washing
slides after hybridization. Acquisition and analysis of
hybridization intensities were performed using Agilent
DNA Microarray Scanner G2505C.
The experiment was performed using a common refer-
ence design, in which the common reference comprised a
pool of equal amounts of RNA from 13 healthy dogs. These
dogs did not take part in the experiment. The cRNA of
common reference samples were Cy3-labelled and the
cRNA of healthy dogs (control group of dogs taking part in
experiment) and of AD dogs were labelled with Cy5.
Twenty eight two-color microarrays were performed, one
for each patient (20 microarrays with samples from AD
dogs and eight from healthy dogs). On each microarray
825 ng of each sample of cRNA (Cy3-labelled common ref-
erence and Cy5-labelled control or patient) were hybridized.
Signal detection and statistical analysis
After microarray scanning, data were extracted and back-
ground subtracted using the standard procedures contained
in the Agilent Feature Extraction (FE) Software version
10.7.3.1. FE performs Lowess normalization.
Prior the analysis of differential gene expression, non-
specific filtering was performed. Transcripts without ex-
pression were removed. In addition, transcripts whose
median of signal in channel R and G (calculated in in-
vestigated and control samples) did not exceed 100 were
identified and eliminated. This reduced the number of
transcript down to 20,188.
The log2-ratio of the sample to common reference sig-
nal was calculated and the data were median-centered
among all microarrays. The analysis of differential expres-
sion was performed using Limma’s method (linear
methods for microarrays) and R/Bioconductor package. A
multiple testing correction was applied using Benjamini
and Hochberg False Discovery Rate (FDR). Microarray
data were deposited at the Gene Expression Omnibus data
repository under the number GSE76119.
To identify signaling pathways and gene function the
microarray data was analyzed using Pathway Studio 11
(Ariadne Genomics). This is a database consisting of mil-
lions of individually modeled relationships between pro-
teins, genes, complexes, cells, tissues and diseases [18].
Real-time RT-PCR
To verify microarray results, the expression of three genes:
PIAS1 (protein inhibitor of activated STAT,1), RORA
(RAR-related orphan receptor A) and SH2B1 (SH2B
adaptor protein 1) was analyzed using real-time PCR. The
sequences of chosen genes were obtained from Ensembl
or NCBI database. Primers were designed using Primer-
Blast software (NCBI database) and verified using Oligo
Calc: Oligonucleotide Properties Calculator (free software
available online, provided by Northwestern University) to
exclude sequences showing self-complementarity. To re-
duce chances of amplifying traces of genomic DNA, the
primers were positioned in different exons. The secondary
structures of the amplicon were examined using m-fold
Web Server (free on-line access). Reference genes:
GAPDH and RPS19 were amplified using primer se-
quences previously published [5, 19, 20]. All primer se-
quences are listed in Table 1. Total RNA was reverse
transcribed to first strand complementary DNA (cDNA)
using the High Capacity cDNA Reverse Transcription
(Applied Biosystems, USA). All analyses were performed
on individual samples of total RNA using SYBR Select
Master Mix (Applied Biosystems, USA) on Stratagene
Mx3005P Quantitative PCR instrument for RT-PCR, fol-
lowing the manufacturer’s protocol. For all genes anneal-
ing temperature was 58 °C. The relative expression of the
target gene was quantified as mean of triplicate measure-
ments for each biological sample. Results were calculated
using the 2-ΔΔCT method [21].
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Results
Lymphocyte subpopulations in peripheral blood of AD
and healthy dogs
The number of cells in specific subpopulations of lym-
phocytes in peripheral blood of dogs with atopic derma-
titis and control group (healthy dogs) was analyzed
using flow cytometry, and are presented in Table 2. The
mean percentage of lymphocytes was similar in both
groups: 45.2 ± 3.3 (AD dogs) and 42.7 ± 6.5 (control).
The percentage contribution of T cells (CD3+) and B
cells in lymphocytes population was significantly smaller
in AD dogs than in control dogs (P = 0.04). The number
of CD3+CD4+ cells within the population of T lympho-
cytes was almost the same in both investigated groups;
whereas the percentage of CD3+CD8+ T cells was
significantly higher in AD dogs than in control group
(P = 0.002). The CD4+/CD8+ cells ratio was signifi-
cantly lower (P = 0.02) in AD dogs than in control an-
imals. The number of CD4+CD25+ Foxp3+ Treg cells
was increased in AD dogs in comparison to the
healthy ones (P < 0.0001).
Cytokine profile in peripheral blood of AD and healthy
dogs
The level of cytokines in plasma of AD and healthy dogs
was determined based on ELISA tests, and the results
obtained are presented in Fig. 1. In four out of seven
analyzed cytokines significant differences were observed
between the two groups of dogs. The level of IL-13 and
TNF-α was significantly higher in AD dogs than in con-
trols (P = 0.02); whereas L-10 was significantly lower in
AD patients (P = 0.03). No differences were noted in the
case of IL-4. In most patients IFN-γ was undetectable,
only in two dogs from each investigated group this cyto-
kine was detected on quite high level. Likewise, cytokine
IL-2 was not detected in all patients, and the concentra-
tion of this interleukin was lower in AD than in control
dogs (P = 0.05). It should be noted that IL-2 was detected
in 9 out of 20 AD dogs, but the values detected exceeded
the detection limit of used ELISA kit (5.8 pg/ml) only in 3
samples. Although no significant difference was noted in
the level of TGF-β1 between both groups of animals, there
was a tendency towards lower values of concentration of
this cytokine in AD dogs (P = 0.55). Detailed information
about the range of detected levels of cytokines and the
number of dogs in which cytokines were detected are pre-
sented in Additional file 1: Table S1.
Microarrays analysis
In order to determine possible differences in gene ex-
pression in peripheral blood nuclear cells of AD and
healthy dogs a microarray analysis was performed. The
analysis revealed 139 differentially expressed transcripts
between two investigated groups: AD and healthy dogs
(FDR-adjuted P value =0.085). Among these 139 differ-
entially expressed transcript only 59 genes have known
Table 1 Primer sequences for real-time PCR verification of microarray result
Gene Forward primer (5'–3') Revers primer (5'–3') NCBI accession number
PIAS1 TGGAGTTGATGGATGCTTGAG GGACACTGGAGATGCTTGAT transcript variant X1-X2: XM_005638536.2 5
XM_535524.5
RORA AAGGCTGCAAGGGCTTTTTC CTGCGTACAAGCTGTCTCTT transcript varian X1- X3: XM_014109378.1
XM_535503.6 XM_014117330.1









GAPDH GGAGAAAGCTGCCAAATATG ACCAGGAAATGAGCTTGACA NM_001003142.1
RPS19 CCTTCCTCAAAAAGTCTGGG GTTCTCATCGTAGGGAGCAAG XM_533657.3
Table 2 Percentage of lymphocyte subsets in peripheral blood
of dogs with atopic dermatitis and healthy dogs
Lymphocytes
subpopulations
% of cells in different subpopulations
of white blood cells
AD dogs Control dogs P value
Lymphocytes 45.2 ± 3.3 42.7 ± 6.5 0.7147
CD3+ 25.67* ± 3.02 35.90 ± 2.65 0.0408
B cells 3.81* ± 0.68 6.24 ± 0.82 0.0373
CD3+ CD4+ 67.40 ± 2.01 70.70 ± 1.94 0,1866
CD3+CD8+ 19.56 ** ± 0.87 14.71 ± 1.11 0.0023
CD4+/CD8+ 3.86* ± 0.33 5.31 ± 0.41 0.0132
CD4+CD25+ Foxp3+ 1.54*** ± 0.18 0.48 ± 0.08 <0.0001
The results are expressed as mean percentage of positive cells ± SEM, ratio
CD4+/CD8+ was calculated as the ratio of absolute number of cells within the
T lymphocytes population, symbol *represents the level of significance:
P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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ontology (Table 3). Even though none of the listed genes
encoded proteins typically involved in the immune re-
sponse, the transcripts showing differential expression
between AD and healthy dogs were directly or indirectly
connected with transcriptional regulation (SMAD2,
RORA) or signal transduction pathways (e.g., VEGF,
SHB21, PROC) taking part in T lymphocytes lineages
differentiation and cytokines synthesis.
Validation of microarray data
To validate the microarray data we selected genes which
were shown to be directly or indirectly involved in regu-
lation of T lymphocytes differentiation, and synthesis of
investigated cytokines. Thus, we chose to analyze the
expression of PIAS1, RORA and SH2B1 genes using real-
time qPCR. The results obtained confirmed the de-
creased expression of all tested genes in AD dogs in
comparison to healthy animals (Fig. 2).
Discussion
In the present study we aimed to perform comprehen-
sive analyses of peripheral blood of AD dogs in relation
to healthy subjects in order to determine the changes
which would be characteristic for cAD. Therefore we
analyzed the number of cells in specific subpopulations
of lymphocytes, determined the concentration of chosen
pro- and anti-inflammatory cytokines, and performed a
microarray analysis to determine the gene expression
profile of peripheral blood nuclear cells in both groups
of dogs. Flow cytometric analyses revealed that the per-
centage contribution of CD3+ T cells and B lymphocytes
in AD dogs was significantly lower than in healthy ones,
the number of CD3+CD4+ T cells in both groups was
similar, and the percentage of CD3+CD8+ lymphocytes
increased significantly in AD dogs. These results did not
confirm previously published reports demonstrating that
patients with cAD have increased number of both
CD3+CD4+ and CD3+CD8+ T cells, since in our study
only the subpopulation of Tc lymphocytes was increased.
However, the majority of studies on dogs have focused
on lymphocytes which infiltrate the atopic skin, showing
the pivotal role of Th1 and Th2 cells in the development
of skin inflammation. It was demonstrated that in
lesional and non-lesional atopic skin the percentage of
CD3+, CD4+ and CD8+ cells increased in comparison
with the skin of healthy dogs, but the presence of B cells
was scarce and detected only in lesional skin [9]. In ca-
nine lesional atopic skin, the predominat type of T lym-
phocytes was CD4+ cells; whereas, in non-lesional atopic
skin an infiltration of both CD4+ and CD8+ T-cells was
observed, without predominance of CD4+ T cells [9, 10].
Hennino et al. [8, 22] reported that CD8+ cells were es-
sential for the development of AD skin inflammation in
both mice and humans. In these studies AD was pro-
voked by the epicutaneos application of house dust
mites (HDM). The authors observed recruitment of CD8+
lymphocytes to the Drematophagoides farine exposed
skin before the infiltration of other leukocytes subsets.
Also in lesional skin of dogs with cutaneous adverse
food reaction (CAFRs) increased number of CD3+CD4+
and CD3+CD8+ cells was observed in comparison to skin
of control dogs. Furthermore, CD3+CD8+ phenotype pre-
dominated over CD3+CD4+ phenotype in these patients.
The study on murine model indicated dual time-
dependent role of CD8+ T cells in development of airway
hyperreactivity (AHR) [23]. The authors observed that at
early stage the CD8+ T cells protected the organism from
systemic sensitization, but when systemic sensitization
Fig. 1 Concentration of cytokines in plasma of dogs with atopic dermatitis and healthy dogs. Symbol * represents the level of significance: P≤ 0.05
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Table 3 The list of differentially regulated genes with known ontology in AD vs healthy dogs
GeneSymbol Description logFC Regulation p-value adj.
NPTXR neuronal pentraxin receptor −1,09 down 0,085
CCDC54 coiled-coil domain containing 54 −1,09 down 0,085
UFL1 UFM1-specific ligase 1 −0,76 down 0,085
BBS2 Bardet-Biedl syndrome 2 −0,68 down 0,085
DCUN1D1 defective in cullin neddylation 1, domain containing 1 −0,66 down 0,085
RORA RAR-related orphan receptor A −0,66 down 0,085
PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta −0,61 down 0,085
OPN1SW opsin 1 (cone pigments), short-wave-sensitive −0,58 down 0,085
FAM49A family with sequence similarity 49, member A −0,58 down 0,085
PURA purine-rich element binding protein A −0,57 down 0,085
CA14 carbonic anhydrase 14-like (LOC100855809), −0,54 down 0,085
SCN1B sodium channel, voltage-gated, type I, beta subunit −0,53 down 0,085
SCOC short coiled-coil protein −0,53 down 0,085
PIWIL4 PIWIL4 piwi-like RNA-mediated gene silencing 4 −0,53 down 0,085
WNT5B wingless-type MMTV integration site family, member 5B −0,53 down 0,085
FAM155B family with sequence similarity 155, member B −0,52 down 0,085
EPHB3 EPH receptor B3 −0,52 down 0,085
LOC100856122 olfactory receptor 4 K5-like −0,52 down 0,085
BPIFB1 BPI fold containing family B, member 1 −0,52 down 0,085
TNKS2 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 −0,51 down 0,085
RTN4RL1 reticulon 4 receptor-like 1 −0,51 down 0,085
TTYH2 tweety family member 2 −0,50 down 0,085
AK9 adenylate kinase 9 −0,50 down 0,085
GPR12 G protein-coupled receptor 124 −0,49 down 0,085
PCIA1 cross-immune reaction antigen −0,49 down 0,085
VEGFA vascular endothelial growth factor A −0,49 down 0,085
OTOP1 otopetrin 1 −0,49 down 0,085
TTF2 transcription termination factor, RNA polymerase II −0,49 down 0,085
FGFBP3 fibroblast growth factor binding protein 3 −0,48 down 0,085
ABHD15 abhydrolase domain containing 15 −0,48 down 0,085
PROC protein C (inactivator of coagulation factors Va and VIIIa) −0,47 down 0,085
EM2 transmembrane protein 25 −0,47 down 0,085
EMC1 ER membrane protein complex subunit 1 −0,47 down 0,085
TMEM52 transmembrane protein 52 −0,47 down 0,085
RHOV ras homolog family member V −0,47 down 0,085
TEKT1 tektin 1 −0,47 down 0,085
GDPD3 glycerophosphodiester phosphodiesterase domain containing 3 −0,47 down 0,085
ANAPC5 anaphase promoting complex subunit 5 [ −0,47 down 0,085
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 −0,46 down 0,085
ZC3H10 zinc finger CCCH-type containing 10 −0,46 down 0,085
SMAD2 SMAD family member 2 −0,46 down 0,085
SSH3 slingshot protein phosphatase 3 −0,46 down 0,085
SH2B1 SH2B adaptor protein 1 −0,45 down 0,085
PIAS1 protein inhibitor of activated STAT, 1 −0,45 down 0,085
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was established, these cells may play a bystander or proin-
flamatory role in the development of allergic airway dis-
ease [23]. There is only a few reports regarding the
subsets of lymphocytes in peripheral blood in atopic dogs.
Tarpatakiet al. [24] indicated an increase of CD4+/CD8+
ratio of T lymphocytes in AD dogs in comparison with
healthy dogs. In contrast, other studies obtained results
which are comparable to our data showing that the per-
centage of CD4+ T cells did not change in atopic dogs in
relation to healthy dogs but percentage of CD8+ T cells
significantly increased and as a result ratio of CD4+/CD8+
T lymphocytes in AD dogs decreased [25]. In German
shepherd dogs suffering from pyoderma (GSP) the per-
centage of CD4+ cells decreased, CD8+ cells increased and
ratio CD4+/CD8+ decreased in comparison to healthy
dogs [26]. Thus, the results showing a marked increase in
CD8+ T cells in peripheral blood of AD dogs suggest that
these lymphocytes may play an important role in skin in-
flammation during AD.
We also observed a significant increase in the percent-
age of Treg cells in dogs with AD in comparison with
healthy controls. Subsets of Treg cells are responsible
for healthy immune response to allergens. These cells
mediate the peripheral tolerance to allergen suppressing
proliferation and activity of effector cells. The population
of Treg cells is heterogeneous by the expression of vari-
ous surface markers and can be subdivided into several
subtypes. The most known subset called naturally occur-
ring regulatory T cells (nTreg cells) was defined based
on expression of surface CD25 (IL-2Rα) and transcrip-
tion factor Foxp3. It was demonstrated that in dogs
CD4+CD25+ Foxp3+ cells were able to suppress the pro-
liferation of responder CD4+ T cells in vitro [27]. Our
study demonstrated that the percentage of circulating
CD4+CD25+ Foxp3+ cells in atopic dogs was significantly
higher compared to healthy dogs, and these results were
similar to recent data of other research groups [28, 29].
On the contrary other investigations have indicated that
the Treg cells are not fully efficient in atopic patients in
comparison with healthy individuals. In vitro studies on T
lymphocytes isolated from human grass allergic donors
showed that Treg cells from these donors failed to inhibit
proliferation but not cytokine production of CD4+CD25−
T cells at high antigen doses, while Treg from non-atopic
donors retained their regulatory properties [30]. It is
possible, however, that the higher percentage of Tregs
Table 3 The list of differentially regulated genes with known ontology in AD vs healthy dogs (Continued)
SUFU suppressor of fused homolog (Drosophila) −0,44 down 0,085
ALKBH4 alkB, alkylation repair homolog 4 (E. coli) A −0,44 down 0,085
NRG2 neuregulin 2 −0,44 down 0,085
TMEM231 transmembrane protein 231 −0,44 down 0,085
OGT OGT O-linked N-acetylglucosamine (GlcNAc) transferase −0,44 down 0,085
RBM25 RNA binding motif protein 25 −0,43 down 0,085
SCN2B sodium channel, voltage-gated, type II, beta subunit −0,42 down 0,085
PTP4A2 protein tyrosine phosphatase type IVA, member 2 −0,42 down 0,085
PEX26 peroxisomal biogenesis factor 2 −0,41 down 0,085
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 −0,40 down 0,085
THEMIS thymocyte selection associated −0,39 down 0,085
ERLIN1 ER lipid raft associated 1 −0,39 down 0,085
DDX1 DEAD (Asp-Glu-Ala-Asp) box helicase 1 −0,39 down 0,085
PABPC5 poly(A) binding protein, cytoplasmic 5 −0,37 down 0,085
CDT1 chromatin licensing and DNA replication factor 1 −0,34 down 0,085
Log fold change (FC) expressed as log2
p-value adj. was adjusted by multiple testing using the Benjamini-Hochberg False discovery rate procedure (FDR) for each comparison
Fig. 2 Expression of PIAS1, RORA, SH2B1 genes in peripheral blood
nuclear cells of AD and healthy dogs analyzed using microarray and
real-time PCR
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detected in AD patients in our study could be related to
the chronic nature of the disease [28].
It has been shown that atopic dermatitis is affected
by aberrant immune response and that imbalance in
the T lymphocytes population and associated cytokine
pattern play a crucial role. Cytokines are very power-
ful messengers, which control regulatory system in all
levels: production, secretion, effect on target. During
allergic inflammation, preformed and newly synthe-
sized cytokines are released and contribute to the
pathological response to allergen. These cytokines
have a wide range of activities on different cell types.
In our study we determined the plasma level of a few
cytokines which take part in development of atopy
and maintain the inflammatory state. In the initial
acute phase of AD eosinophils and Th2 cells are the
predominant subpopulation of immune cells, and in-
creased production of IL-4, IL-5, IL-13 is observed. In
chronic AD lesions there is a switch towards Th1
cells secreting IFN-γ and IL-12 and also IL-2. In
some studies it was indicated that chronic phase is
not characterized only by the presence of Th1 cells
but rather by a mixed Th1 and Th2 profile [4, 5]. It
results from a dynamic nature of this process.
In our study it is difficult to define the phase of im-
mune response. The pattern of cytokines’ concentration
in plasma partially indicates the domination of Th-2
cells subpopulation, but the interpretation is not obvi-
ous. We noted a significantly higher level of IL-13, and
slightly elevated concentration of IL-4 in AD dogs in
comparison to healthy controls. Similar results were pre-
sented by Schlotter [5], who observed increased expres-
sion of IL-13 mRNA in lesional skin and non lesional
skin of AD dogs, but an unchanged expression of IL-4
gene. Increase expression of IL-13 mRNA was also
noted in the skin of dogs challenged with house dust
mites (HDM) allergen for 24 and 48 h, while the expres-
sion of other interleukins secreted by Th-2 cells was low
and the level did not change significantly in time [31]. In
addition, in humans after HDM allergen challenge secre-
tion of IL-13 to the peripheral blood also occurred earl-
ier and for much longer time than in the case of IL-4
[32, 33]. These results suggest that IL-13 may play more
important role in atopic response than IL-4.
In the present study IFN-γ, considered as the “canon-
ical” Th1 cytokine, was detected only in two healthy and
two AD dogs. We presume that the level of IFN-γ in
plasma may be a characteristic feature of each individual.
In fact, among dogs exposed to immunotherapy IFN-γ
was detected only in the same two dogs in which this
cytokine was detected prior therapy (data not show).
Similar observations were made by Hayashiya et al. [34],
who detected IFN-γ mRNA expression in PBMC of nine
out of ten control dogs and in two out of eight AD dogs,
and the average expression of IFN-γ mRNA was lower
in AD dogs. The production of IFN-γ may be related to
the stage of development of skin lesions and the type of
investigated tissue. In the skin of dogs exposed to epicuta-
neous allergen challenge IFN-γ mRNA expression was the
highest at the early time points post challenge (6 h) and
after 4 days, whereas at the intermediate period the ex-
pression of this cytokine was at a low level [31]. This ob-
servation shows the dynamic nature of IFN-γ induction.
On the other hand, we noted a significantly higher
concentration of TNF-α in plasma of atopic dogs then in
healthy animals. This result seems to be directly con-
nected with the state of atopic inflammation in investi-
gated AD dogs. TNF-α is a pleiotropic cytokine, which
plays a key role in bridging innate and adaptive immun-
ity in chronic inflammatory disease [35]. Excessive secre-
tion of this cytokine is associates with susceptibility to
allergies. There are many potential sources of TNF-α:
macrophages, T lymphocytes, mast cells, eosinophils and
neutrophils [36]. In atopy disease TNF-α is frequently
recognized as a cytokine that belongs to the Th1-type
profile. TNF-α is non-specific proinflamatory mediator,
inducing expression of cell adhesion molecules and
eotaxins effecting recruitment of eosinophils, neutro-
phils, and macrophages to the sites of allergic inflamma-
tion. Furthermore, it increases the proliferation of B and
T lymphocytes, and is able to induce apoptosis of kerati-
nocytes. Additionally, TNF-α impairs the regulatory ac-
tivity of natural Treg cells via the TNF-α receptor 2
(TNFR2) signaling pathway to down-modulate Foxp3
expression in allergic asthma [37]. Our results are in
agreement with a previous study by Nuttall et al. [4]
who observed increased expression of TNF-α mRNA in
lesional skin of atopic dogs in comparison to the non-
lesional and healthy control tissue.
In contrast to TNF-α concentration the level of IL-2
in plasma of AD dogs was reduced in comparison to
healthy group, but the level of this cytokine was gener-
ally undetectable in majority of samples. IL-2 is secreted
by Th1 cells, and it is a growth factor essential for prolif-
eration, survival and function of both effector T cells
(Teffs) and Treg cells [38–40]. Treg cells do not produce
IL-2 but this interleukin is required for their activation
by regulating Foxp3 expression via signaling transducer
and activator of transcription 5 (STAT5) [41–44]. How-
ever, Foxp3 represses the expression of IL-2 and acti-
vates expression of CD25 genes (IL-2 receptor) by
binding to the promoter of these genes [42–45]. Tregs
also inhibit production of IL-2 in Teffs, and additionally
they have a high expression of IL-2 receptors (CD25)
which gives them the capacity to compete with Teffs for
IL-2 [40, 44, 46, 47]. Research describing the function of
IL-2 in the skin of AD dogs demonstrated that the ex-
pression of IL-2 mRNA was increased in lesional skin in
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comparison to non-lesional and and healthy cutaneous
tissue [4]. In our study a decrease of IL-2 concentration in
blood plasma of AD dogs coincided with increase number
of Treg cells in these animals, suggesting the suppressive
effect of Treg lymphocytes. However, AD dogs also had
lower plasma levels of two anti-inflammatory cytokines:
IL-10 and TGF-β1, which is contradictory to the concept
of suppressive effect of the immune response. Both of
these anti-inflammatory cytokines secreted by Treg cells
suppress allergen-induced specific T-cell activation and al-
lergic processes. IL-10 is synthesized by a wide range of
cells besides Tregs: Th2 cells, B cells, monocytes,
dendritic cells, and mast cells. It inhibits the production of
proinflammatory cytokines and cytokine receptors [13,
48]. IL-10 is also a potent suppressor of allergen-specific
IgE, simultaneously inducing IgG4 production by a direct
influence of Tregs on B-cells. Most studies regarding cAD
do not report any differences in plasma concentration of
IL-10 between AD and healthy dogs [49], or in the expres-
sion of IL-10 mRNA in lesional and non-lesional skin [4],
or in circulating PBMCs [34]. However, Maeda et al. [50]
observed decreased IL-10 expression in blood of cAD pa-
tients during allergen challenge, which is consistent with
our results. TGF-β1 is secreted by Tregs and also similarly
to IL-2 it converts naïve T cells to Treg cells by inducing
the expression of Foxp3. TGF-β1 together with IL-6 con-
tributes to the generation of Th17 cells [51]. TGF-β1 in-
hibits the proliferation, differentiation, and survival of
both B and T lymphocytes [48]. Membrane-bound TGF-
β1 shows unique and potent immunosuppressive activity
towards Tregs, associated with direct contact of TGF-β1
with its receptors localized on Treg cell membrane. Upon
activation of TGF-β1 receptor type II (TbRII), Treg cells
become susceptible to TGF-β1 and demonstrate activation
of TGF-β1 - dependent transcription factors (Smads). The
Treg membrane-associated TGF-β1 might provide a sus-
tained contact-dependent signal crucial to suppressing ef-
fector T cells and mediating cell cycle arrest, and blocking
cytokine production. In addition to contact-dependent
suppression of TbRII-expressing responder T cells, soluble
TGF-β1 shows many direct effects on cells of the immune
system, including regulation of macrophage activation,
dendritic cell maturation, T-cell proliferation and cytokine
generation, and B-cell antibody production [52]. Neverthe-
less, the role of TGF-β1 in cAD has not been fully eluci-
dated, and the results published so far are often
contradictory. Schlotter et al. [5] did not observe any dif-
ference in the expression of this cytokine in lesional and
non-lesional skin of AD dogs as well as control skin sam-
ples. On the other hand Nuttall el al. [4] demonstrated
lower expression of TGF-β1 in lesional and non-lesional
skin in comparison to control tissue. In blood of patients
undergoing allergen challenge the level of TGF-β1 mRNA
decreased after four days, which is similar to our
observations [50]. Findings of the present study indicate
that despite increased number of Treg cells (CD4+CD25+
Foxp3+) detected in AD dogs the level of anti-
inflammatory cytokines produced by these cells was insuf-
ficient to protect the organism against the pathological im-
mune response.
In the last stage of our study we performed a micro-
array analysis in order to compare the transcriptomic
profile of peripheral blood nuclear cells in AD and
healthy dogs. Even though we did not detect any
changes in the mRNA expression level of investigated
cytokines, the genes showing differential expression be-
tween AD and healthy dogs were directly or indirectly
connected with regulation of T lymphocytes lineages dif-
ferentiation and synthesis, as well as secretion of the
aforementioned cytokines. Pathway studio analyses
enabled us to find the interactions between the differen-
tially expressed genes and cytokines investigated in the
present study (Fig. 3).
Among the differentially expressed genes which
showed the highest number of interactions with other
genes was VEGFA encoding vascular endothelial growth
factor (isoform A). VEGF is known to be one of the
principle mediators of angiogenesis, fibroblast stimula-
tion and tissue remodeling in allergic conditions. It may
also stimulate inflammatory cell recruitment, enhance
antigen sensitization and appear crucial for adaptive Th-
2 inflammation [53]. A few studies demonstrated the
connection between VEGF synthesis and human AD
skin lesions [54]. VEGF may play a role in the pathogen-
esis of AD and be involved in regulation of AD lesions
development acting possibly in the persisting erythema
and edema by prolonged capillary dilatation and hyper-
permeability [54]. Koczy-Baron et al. [55] have shown a
significant increase in VEGF plasma levels in human AD
patients in comparison to controls. However, these au-
thors did not find any correlation between the plasma
levels of VEGF and the number of cells that contribute
to the secretion of this growth factor (mast cells, plate-
lets). In our study the expression of VEGFA was
decreased in peripheral blood nuclear cells of cAD pa-
tients. It is worth noting that the difference in VEGFA
expression was observed despite similar numbers of
blood elements (platelets, white blood cells) in both in-
vestigated groups of dogs (data not shown). It is possible
that the role of VEGF is predominant at the site of
inflammation (skin lesions) and blood levels of this
growth factor are not a suitable prognostic marker of AD.
Similar conclusion was stated in the work of Koczy-
Baron et al. [55]. Interestingly, VEGF expression is
stimulated by TGF-β1-induced signaling pathway, in
which Smad2 and Smad3 become activated and form
heterocomplexes with Smad4, enabling their trans-
location to the nucleus and function as transcription
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activators [52, 56, 57]. In our study plasma concentration
of TGF-β1 did not differ significantly between AD and
healthy dogs, whereas SMAD2 expression was downregu-
lated in cAD patients, correlating with the decreased ex-
pression of VEGF detected in AD dogs. These results are
in agreement with the studies showing direct relationship
between the VEGF expression and TGF-β1-induced
Smad2 signaling [58] (Fig. 3).
PIAS1 (protein inhibitor of activated STAT1) is an-
other gene whose protein product is directly involved in
regulation of transcriptional activity of Smad2 function.
It has been shown that PIAS1 modulates activation of
Smad2/4 complex and further promotes Smad2/4 medi-
ated proliferation inhibition observed in some cancer
cells [59]. Thus, downregulation of SMAD2 expression
observed in AD patients may be also connected with
decrease levels of PIAS1 mRNA.
RORα encoded by RORA gene was also among tran-
scription factors differentially expressed in dogs with AD
in comparison to controls. RORα belongs to a family of
retinoid-related orphan receptors (RORs) that regulate
gene transcription by binding to specific DNA response
elements (ROREs) [60, 61]. RORs can function both as
repressors and activators of gene transcription, interacting
with corepressors, as well as coactivators of transcription.
It has been demonstrated that a direct interaction of
Foxp3 and RORα results in repression of RORα -mediated
transcriptional activation [62] (Fig. 3). Studies with the use
of stragger (sg/sg) mice, which show a congenital defi-
ciency of the RORα (RORαsg/sg), demonstrated that these
mice had significantly smaller spleen and the thymus, sug-
gesting that RORα may have a role in regulation of thymo-
poiesis and lymphocyte development [63]. In fact, the
number of mature T and B lymphocytes was significantly
reduced in RORα-/-spleen, indicating a significant role of
RORα in lymphocyte development. It has been shown that
Th17 differentiation is dependent on RORs, as RORs in-
duce the expression of IL-17 cytokine gene [64]. On the
other hand, Delerive et al. [65] demonstrated that RORα1
negatively regulated the inflammatory response by interfer-
ing with NFkB signaling pathway in primary aortic smooth
muscle cells. RORα1 belongs to transcription factors which
induce the expression of IkB, the major inhibitory protein
of NFkB activity. Since TNF-α expression is induced by
NFkB signaling pathway, RORα1 actions contribute to at-
tenuation of TNF-α-induced inflammatory response [65].
In our study the plasma concentration of TNF-α signifi-
cantly increased, whereas RORA expression was downregu-
lated in AD dogs. Furthermore, it has been recently
reported that RORα is involved in transactivation of IL-10
promoter boosting the generation of protective Tr1 cells
[66]. Our results relate to these recent findings, demon-
strating that decreased concentration of IL-10 in dogs with
AD coincided with downregulation of RORA expression.
Fig. 3 Interactions between cytokines and selected genes differentially expressed in AD and healthy dogs. Detailed network of interactions
generated using Pathway Studio analysis between genes showing differences in expression in peripheral blood nuclear cells of AD and healthy
dogs (green highlights) and cytokines investigated in this study
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Increased levels of TNF-α in AD dogs may also be
connected with downregulation of PROC gene, which
codes for protein C, a zymogen whose active form (APC
– activated protein C) plays an important role in regulat-
ing anticoagulation, inflammation and cell death [67].
Several studies have demonstrated that TNF-α inhibits
activation of protein C, thereby affecting the coagulation
process [68–70].
Among the investigated cytokines IL-2, IL-10 and
INF-γ showed lower concentration in the blood plasma
of AD dogs than in healthy animals. These cytokines act
via JAK/STAT signaling pathway, in which SH2B1 (SH2
domain-containing protein) protein is recognized to play
a role of a potent activator of JAK2 kinase [71]. Upon
ligand binding to cytokine receptors, JAKs phosphorylate
themselves and their associated receptors, thereby pro-
viding multiple binding sites for signaling proteins con-
taining SH2 or other phosphotyrosine-binding domains
[72]. SH2B1 was shown to be a potent activator of JAK2
associating with JAK2 via its SH2 domain, and thereby
increasing the phosphorylation of JAK2 and its down-
stream targets belonging to the family of STAT tran-
scription fatcors [71, 72]. Downregulation of SH2B1
gene expression detected in dogs with AD can be con-
nected with the decreased levels of cytokines, which act
as ligands activating the JAK/STAT signaling pathway in
the immune cells of peripheral blood.
Results of the presented microarray experiment, ana-
lyzing the transcriptomic profile of peripheral blood nu-
clear cells in AD and healthy dogs, are not in direct
correlation with the previously published studies com-
paring the profiles of gene expression in biopsies of
lesional skin of cAD patients and normal skin samples
derived from healthy dogs [15–17]. It is evident that
more pronounced differences in gene expression were
recognized in the cutaneous tissue, which is the direct site
of inflammatory processes occurring in AD. Authors of the
aforementioned studies observed increased expression of
genes involved in inflammation, wound healing, immune
response [15, 17], associated with alternatively activated
monocyte-derived cells, IL-1 and interferon signaling path-
ways [16], as well as playing a role in apoptosis, barrier for-
mation and transcriptional regulation [15]. All genes
identified in our study were downregulated in AD dogs,
and the protein products of differentially expressed
mRNAs are involved in transcriptional regulation (transcri-
tipon factors: Smad2, RORα) or signal transduction (VEGF,
SHB21, protein C). Juxtaposing the data obtained in the
present study with results published previously suggests
that transcriptomic profile of peripheral blood nuclear cells
does not fully reflect the inflammatory processes which are
primarily induced in the cutaneous tissue. Most probably it
is caused by recruitment of the activated immune cells to
the site of inflammation, thus the significant changes in
gene expression will be noted especially in the lesional skin.
Nevertheless, obtaining biopsies from dogs with severe AD
symptoms is often problematic, and blood samples are still
regarded as the valuable source of information about the
state of the organism. Thus, further investigation should be
done to evaluate the role of detected genes in canine atopic
dermatitis.
Conclusions
In the present study dogs with atopic dermatitis
showed increased number of CD8+ T cells in peripheral
blood, which may suggest that in addition to the com-
monly accepted role of the imbalance between Th1 and
Th2 cells in the immune response during AD, Tc lympho-
cytes may also significantly contribute to the development
of the immunoinflammatory response. Furthermore, ob-
served increase in IL-13 concentration in the blood
plasma of AD dogs in comparison to healthy animals, and
an insignificant difference in the level of IL-4 between
healthy and atopic individuals, support the hypothesis
about the role of IL-13 as a more important mediator of
the physiological changes induced by allergic inflamma-
tion. High concentrations of TNF-α detected in plasma of
atopic dogs additionally confirmed the ongoing allergic in-
flammatory response in cAD patients. Although the num-
ber of detected Treg cells was higher in AD dogs than in
healthy controls, the increased levels of TNF-α indicates
the functional insufficiency of Treg cells in patients with
AD, which may also explain the observed lower concen-
trations of IL-10 and TGF-β1 in the plasma of atopic dogs.
Finally, microarray analysis of the difference in transcrip-
tomic profile of peripheral blood nuclear cells of AD and
healthy dogs revealed 59 genes downregulated in AD
dogs. The list of differentially expressed genes did not in-
clude any cytokines taking part in allergic inflammation;
however the function of identified genes was directly or
indirectly connected with regulation of T lymphocytes lin-
eages differentiation and synthesis, as well as secretion of
the aforementioned cytokines.
Observed changes in the levels of chosen cytokines
(especially IL-13) and the number of immune cells (e.g.,
CD8+ lymphocytes and Tregs) in peripheral blood of
AD dogs encourage further investigations of possible
correlations between cytokines profiles and particular
stage of atopic dermatitis development. Such studies
utilizing larger number of dogs may reveal potential
blood markers helpful in AD diagnosis and determining
adequate treatment of this disease.
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